AtomVie Global Radiopharma

What AtomVie Global Radiopharma does

AtomVie Global Radiopharma Inc. is a Canadian contract development and manufacturing organization (CDMO) that provides cGMP manufacturing and global distribution of radiopharmaceuticals for pharmaceutical and biotechnology clients. Spun out of the Centre for Probe Development and Commercialization (CPDC) in August 2022 and headquartered in Hamilton, Ontario, the company carries forward more than a decade of radiopharmaceutical manufacturing expertise, with a workforce of 101–250 including 60+ quality professionals and PhD-level radiochemists. Its service portfolio spans six integrated offerings: process and analytical method development and validation, quality operations (QC/QA/microbiology), regulatory affairs, clinical supply, commercial supply, and global logistics. Manufacturing capabilities cover multi-isotope radiolabeling with Lu-177, Ac-225, I-131, In-111, Zr-89, Tb-161, and Y-90 across ligands ranging from small molecules and peptides to antibodies.

AtomVie's revenue model is contract-based fee-for-service CDMO work, with contracts covering clinical and commercial manufacturing, process development, regulatory submissions, and logistics. The company serves radiopharmaceutical developers across preclinical through Phase III and commercial stages, delivering to 28 countries on six continents with >99% on-time accuracy and turnaround of 72 hours or less. Named enterprise clients include Radiopharm Theranostics, Cellectar Biosciences, POINT Biopharma, and Ariceum Therapeutics. The regulatory team has filed 525+ submissions to Health Canada and the FDA and has cleared 20+ audits by regulators and clients. AtomVie is pre-sellinng clinical and commercial capacity at its new 72,300 sq ft purpose-built facility, scheduled for operational readiness in 2026, which will expand capacity at least 10x over its current footprint. The company is privately held and has raised over $130 million in Series A financing across two tranches led by Avego Management, with co-investors including Genesys Capital and TURNER Group; the Board includes representatives from Avego, Genesys Capital, TURNER Group, and CEO Bruno Paquin.

Name

AtomVie Global Radiopharma

Legal name

AtomVie Global Radiopharma Inc.

Website

https://atomvie.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

AtomVie Global Radiopharma is a Canadian contract development and manufacturing organization (CDMO) providing cGMP manufacturing and global distribution of radiopharmaceuticals for pharmaceutical and biotechnology companies developing radioligand therapies and radiotherapeutics.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

akta.pro secondary industries

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution) (HLAIAGAH)

Keywords

• Radiopharmaceutical manufacturing
• Contract development manufacturing
• CGMP radiolabeling
• Clinical supply logistics
• Regulatory submissions services

Headquarters

HQ city

Hamilton

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Supply Chain, Technology or R&D

Revenue model

1. Contract Manufacturing Services: AtomVie provides cGMP manufacturing and global distribution of radiopharmaceuticals as a CDMO. Revenue is generated through manufacturing service contracts for clinical and commercial production, including process development, quality operations, regulatory services, and logistics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

AtomVie Global Radiopharma is a Contract Development and Manufacturing Organization (CDMO) providing cGMP manufacturing and global distribution services for radiopharmaceuticals. Its core offerings include process and analytical method development, quality operations, regulatory affairs, clinical supply (Phase I-III), commercial supply, and global logistics, serving pharmaceutical and biotech companies developing radioligand therapies and radiotherapeutics with isotopes such as Lu-177, Ac-225, I-131, In-111, and Zr-89.

Product overview

AtomVie Global Radiopharma Inc. is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive services for radiopharmaceutical manufacturing and global distribution. The company offers an integrated service portfolio comprising six core offerings: Process & Analytical Method Development & Validation (radiolabeling with isotopes including Lu-177, Ac-225, I-131, In-111, Zr-89); Quality Operations (cGMP compliance); Regulatory Affairs (525+ submissions filed); Clinical Supply (4,000+ doses delivered); Commercial Supply (new 72,300 sq ft facility opening 2026); and Logistics (global distribution to 28 countries). These services work together to support clients from Phase 1 clinical development through commercial marketplace launch.

Differentiator

Problem solved

Functional benefit

Products and services

• Process & Analytical Method Development & Validation cGMP radiopharmaceutical manufacturing services including expertise in radiolabeling with radioisotopes such as Lu-177, Ac-225, I-131, In-111, and Zr-89, and ligands ranging from small molecules to peptides and antibodies. Supports early process development, tech transfer, formulation optimization, scale-up, and stability studies for pharmaceutical and biotech clients.
• Quality Operations Quality Control, Quality Assurance, and Microbiology services ensuring compliance with current Good Manufacturing Practices (cGMP) guidelines including Canadian, US, and EU GMP requirements, staffed by 60+ quality professionals.
• Regulatory Services Regulatory affairs support including preparation and filing of submissions to Health Canada and FDA, CMC sections, clinical documents, product monographs, labeling, gap analyses, and pharmacovigilance activities. The team has filed over 525 submissions.
• Clinical Supply Clinical supply services for Phase I to Phase III clinical trials worldwide. Delivered 4,000+ doses since 2023 with >99% accuracy across 28 countries and 6 continents within 72 hours or less.
• Commercial Supply Commercial manufacturing services from the new 72,300 sq ft state-of-the-art facility opening in 2026, with 10x more capacity than current operations. Licensed for Lu-177, Ac-225, I-131, In-111, Tb-161, Y-90 and other isotopes.
• Logistics Global logistics services delivering radiopharmaceuticals to 28 countries across North America, South America, Europe, Asia, Africa, and Australia with just-in-time delivery capabilities and >99% accuracy.

Quantifiable outcome

• >99% accuracy in dose delivery across 28 countries within 72 hours or less
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• Ionetix CorporationcoreOthers · 18 December 2025Strategic supply agreement for GMP-quality Actinium-225 (Ac-225), an alpha-emitting radioisotope, for use in AtomVie's client radiopharmaceutical development and manufacturing programs. This partnership strengthens supply chain reliability and accelerates clinical advancement of targeted alpha therapies.
• TerraPower IsotopescoreOthers · 17 June 2025Strategic supply agreement for Actinium-225 to advance radiopharmaceutical development and manufacturing, supporting the growth of alpha-based therapies.
• Eckert & ZieglercoreOthers · 20 March 2025Global agreement for Lutetium-177 supply to support AtomVie's radiopharmaceutical manufacturing operations.
• Radiopharm TheranosticscoreStrategic or Co-development Partner · 1 October 2024Partnership to develop and manufacture 177Lu-BetaBart radioantibody for treatment of multiple solid tumors. AtomVie provided GMP manufacturing and distribution services for Phase 1/2a clinical trial.
• RLS (Radiology Linear Services) & UPPIsupportingChannel Partner/ Reseller/ Distributor · 1 July 2024Collaboration to strengthen existing U.S. radiotherapeutic distribution network for clinical supply.
• McMaster University & TerumosupportingStrategic or Co-development Partner · 1 January 2023Partnership to manufacture medical devices for cancer treatment in collaboration with McMaster and Terumo.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Curium Pharma: Curium is the world's largest pure-play radiopharmaceutical manufacturer, offering contract manufacturing and global distribution of diagnostic and therapeutic radiopharmaceuticals across SPECT, PET, and therapeutic isotopes — directly overlapping AtomVie's CDMO service portfolio and global distribution footprint.
• PETNET Solutions (Siemens Healthineers): PETNET Solutions operates one of the largest PET radiopharma manufacturing and distribution networks globally, serving hospitals and clinical trial sponsors. It is a direct competitor to AtomVie's clinical supply and global logistics services for diagnostic and therapeutic radiopharmaceuticals.
• Cardinal Health Nuclear & Precision Health: Cardinal Health distributes radiopharmaceuticals to U.S. hospitals and operates manufacturing and radiopharmacy services — directly comparable to AtomVie's North American clinical/commercial supply and global logistics offerings for therapeutic radiopharmaceuticals.
• Eckert & Ziegler: Eckert & Ziegler is both a Lu-177 supplier to AtomVie and an independent radiopharma CDMO via its Medical segment. It directly competes for radiopharmaceutical contract manufacturing business while also serving as an ecosystem partner.

Emerging players

• SpectronRx: SpectronRx is an emerging U.S.-based CDMO providing radiopharmaceutical contract development, manufacturing, and distribution including alpha and beta emitters — directly competing with AtomVie for biotech CDMO clients, particularly in the alpha-therapy space.
• Nucleus RadioPharma: Nucleus RadioPharma is a purpose-built radiopharma CDMO developing a nationwide network of manufacturing facilities for therapeutic radiopharmaceuticals. It competes with AtomVie for emerging biotech outsourcing relationships and capital.
• NorthStar Medical Radioisotopes: NorthStar is a U.S.-based radioisotope production company focused on Mo-99/Tc-99m and emerging therapeutic isotopes. It competes with AtomVie in the broader radiopharma supply chain, particularly for therapeutic isotope production capacity.

Broad incumbents

• Lantheus Holdings: Lantheus is a leading radiopharmaceutical-focused company with in-house manufacturing and a portfolio including PNT2002/PSMA assets. While it primarily develops its own products rather than serving as a CDMO, it overlaps AtomVie's radiopharmaceutical manufacturing capabilities and competes for talent and isotope supply.
• GE HealthCare (Pharmaceutical Diagnostics / Radiopharma): GE HealthCare operates a global PET radiotracer production network through its Pharmaceutical Diagnostics segment. It is a broad incumbent that overlaps AtomVie's radiopharma manufacturing and distribution, though from a much larger scale and broader portfolio base.
• IBA (Ion Beam Applications): IBA is a major player in radioisotope production and radiopharma solutions, including PET isotope supply and emerging therapeutic isotope capabilities. It overlaps AtomVie's upstream isotope production and downstream manufacturing exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/atomvie

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AtomVie Global Radiopharma